Table 4.
Odds Ratios (ORs) and 95% Confience Intervals (CIs) for Biliary Tract Cancer in relation to APOB and LDLR haplotypes
| Biliary Tract Cancers | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Haplotype | Controls | Gallbladder1 | Bile Duct2 | Ampulla of Vater2 | ||||||||||||
| n | (%) | n | (%) | OR3 | (95%CI)3 | n | (%) | OR3 | (95%CI)3 | n | (%) | OR3 | (95%CI)3 | ||||
| Total # | Haplotypes | 1558 | (100.0) | 470 | (100.0) | - | - | 250 | (100.0) | - | - | 92 | (100.0) | - | - | ||
| APOB | EX26-3573T>C - IVS23-79T>C | ||||||||||||||||
| T-T | 1165 | (74.8) | 356 | (75.7) | 1.00 | - | 183 | (73.2) | 1.00 | - | 66 | (71.7) | 1.00 | - | |||
| C-C | 385 | (24.7) | 114 | (24.3) | 0.98 | (0.77–1.25) | 67 | (26.8) | 1.11 | (0.82–1.51) | 25 | (27.0) | 1.13 | (0.71–1.82) | |||
| Other 4 | 8 | (0.5) | 0 | (0.0) | - | - | 0 | (0.0) | - | - | 1 | (1.3) | - | - | |||
| P 5 | 0.40 | 0.50 | <0.001 | ||||||||||||||
| APOB | IVS6+360C>T - EX4+56C>T | ||||||||||||||||
| C-C | 1251 | (80.3) | 376 | (80.0) | 1.00 | - | 189 | (75.5) | 1.00 | - | 73 | (79.4) | 1.00 | - | |||
| T-T | 184 | (11.8) | 51 | (10.9) | 1.18 | (0.77–1.82) | 43 | (17.0) | 1.58 | (1.07–2.33) | 9 | (9.8) | 0.87 | (0.42–1.81) | |||
| T-C | 90 | (5.8) | 34 | (7.3) | 0.91 | (0.65–1.27) | 17 | (6.6) | 1.21 | (0.70–2.10) | 5 | (5.4) | 0.84 | (0.30–2.39) | |||
| Other 4 | 33 | (2.1) | 8 | (1.8) | - | - | 2 | (0.9) | - | - | 5 | (5.4) | 3.1 | (1.12–8.61) | |||
| P 5 | 0.76 | 0.05 | 0.12 | ||||||||||||||
| IVS9-30C>T - EX10+55G>A - | |||||||||||||||||
| EX15-80G>A - IVS17-42A>G - | |||||||||||||||||
| LDLR | EX18+88G>A | ||||||||||||||||
| C-A-G-A-A | 458 | (29.4) | 145 | (30.8) | 1.00 | - | 76 | (30.5) | 1.00 | - | 33 | (35.8) | 1.00 | - | |||
| C-G-G-A-G | 430 | (27.6) | 116 | (24.6) | 0.86 | (0.65–1.14) | 70 | (27.8) | 0.96 | (0.68–1.37) | 10 | (10.8) | 0.38 | (0.19–0.76) | |||
| C-G-G-G-G | 168 | (10.8) | 67 | (14.2) | 1.07 | (0.76–1.51) | 27 | (10.8) | 0.80 | (0.50–1.26) | 20 | (21.7) | 1.16 | (0.65–2.06) | |||
| T-G-G-G-G | 185 | (11.9) | 54 | (11.4) | 0.89 | (0.62–1.29) | 45 | (17.8) | 1.43 | (0.95–2.17) | 7 | (7.6) | 0.46 | (0.19–1.09) | |||
| C-G-G-A-A | 109 | (7.0) | 27 | (5.8) | 0.83 | (0.51–1.35) | 16 | (6.3) | 0.83 | (0.45–1.55) | 14 | (15.2) | 1.60 | (0.79–3.22) | |||
| C-A-A-A-G | 50 | (3.2) | 28 | (6.0) | 1.06 | (0.67–1.68) | 8 | (3.2) | 0.64 | (0.30–1.33) | 4 | (4.3) | - | - | |||
| Other 4 | 157 | (10.1) | 34 | (7.2) | 1.38 | (0.85–2.24) | 9 | (3.6) | 0.70 | (0.31–1.57) | 4 | (4.6) | - | - | |||
| P 5 | 0.04 | 1.00 | 0.001 | ||||||||||||||
1
Gallbadder cancer cases compared with population controls who had a gallbladder (n=730)
2
Bile duct and ampulla of Vater cancer cases compared to all population controls (n=779)
3
Adjusted for age
4
Combined haplotypes having frequency <1% among population controls
5
Omnibus score test